江苏吴中医药发展股份有限公司关于股票交易暨重大违法强制退市风险提示公告

Group 1 - The company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) on July 13, 2025, indicating that it inflated operating income, operating costs, and profits, which may lead to a forced delisting due to serious violations [1][2] - The company's stock has been subject to delisting risk warnings since July 14, 2025, due to the potential for serious violations that could result in termination of listing [2] - The 2024 annual financial report received a disclaimer of opinion from the auditing firm, triggering financial delisting risk warnings under the Shanghai Stock Exchange rules [2][3] Group 2 - The company is facing additional risk warnings due to internal control issues in the 2024 financial report and non-operational fund occupation by related parties [3] - A contract termination notice was sent to the company's subsidiary, affecting the sales of AestheFill products, which may impact revenue [4] - The controlling shareholder's shares are fully pledged or frozen, indicating significant financial strain and potential liquidity issues [4][5]